Zolbetuximab Biosimilar – Anti-CLDN18.2 mAb – Research Grade

Reference:
Product nameZolbetuximab Biosimilar - Anti-CLDN18.2 mAb - Research Grade
SourceDrugBank DB15118
SpeciesHuman
Molecular weightLC: 26kDa
HC:51kDa
Purity>85%
BufferPBS pH7.5
Delivery conditionBlue ice (+4°C)
Delivery Time3-5 days if in stock; 3-5 weeks if production needed
Storage condition4°C for short term; -20°C for long term
BrandProteoGenix
ApplicationsELISA,WB
Aliases /SynonymsZolbetuximab,Zolbetuximab,CLDN18.2,anti-CLDN18.2
ReferencePX-TA1013
NoteFor research use only. Not suitable for clinical or therapeutic use.
IsotypeIgG1
ClonalityMonoclonal Antibody

Description of Zolbetuximab Biosimilar - Anti-CLDN18.2 mAb - Research Grade

General information about Zolbetuximab

Zolbetiximab is a monoclonal antibody currently under investigation as a potential treatment for pancreatic tumors and gastrointestinal adenocarcinomas. This therapeutic antibody targets isoform 2 of Claudin-18. Claudin-18 protein is encoded by CLDN18 gene and is a member of claudin family of proteins. The members of this family of proteins are key components in the structure of tight junctions also known as zonulae occludentes. Tight junctions form the paracellular space which is the intercellular space between epithelial cells. Claudin family of proteins contain four transmembrane domain whose C-terminus and N-terminus are both located in the cytoplasm. The isoform 2 of CLDN18 protein is restricted to differentiated epithelial cells located at the gastric mucosa tight junctions. However, once malignant transformation occurs, the cell polarity is disturbed and results in isoform 2 CLD18 epitopes being exposed on the surface of cancer cells. Hence, isoform 2 of CLDN18 has been considered as a potential candidate for in targeted therapy for different forms of cancer such as esophagus, pancreatic, ovarian and lung tumors.
Zolbetiximab binds to isoform 2 CLDN18 which results in immune-mediated lysis of this protein. The attachment of Zolbetiximab to isoform 2 CLDN18 causes cancer cell death as a result. Zolbetiximab was in phase II clinical trials as of January 2013. Preliminary results based on phase II ‘FAST’ trial supported zolbetiximab as a potential drug for advanced gastric cancer. Currently zolbetiximab is in phase III of clinical trials. So far zolbetuximab therapy has been well tolerated, Furthermore, the monoclonal antibody showed antitumor activity among patient with isoform 2 CLDN18-positive advanced gastric or gastroesophageal junction cancers. The phase III study consists of administering Zolbetiximab plus mFOLFOX6 vs placebo plus mFOLFOX6. mFOLFOX6 is a combination of three different chemotherapies such as Oxaliplatin, Leucovorin, and Fluorouracil which are also a current treatment option for patients with advanced gastric or gastroesophageal junction adenocarcinoma or cancer. This product is for research use only.

SDS-PAGE for Zolbetuximab Biosimilar - Anti-CLDN18.2 mAb

Zolbetuximab Biosimilar - Anti-CLDN18.2 mAb, on SDS-PAGE under reducing and non-reducing condition. The gel was stained overnight with Coomassie Blue. The purity of the antibody is greater than 95%.

Reviews

There are no reviews yet.

REVIEW YOUR PRODUCT

Be the first to review “Zolbetuximab Biosimilar – Anti-CLDN18.2 mAb – Research Grade”

Your email address will not be published. Required fields are marked *

Related products

Claudin-18 (CLDN18)
Antigen

Claudin-18 (CLDN18)

PX-P4673 221$
Human IgG1 LALA Isotype Control antibody (HyHEL-10)
Isotype Control

Human IgG1 LALA Isotype Control antibody (HyHEL-10)

PTX17885 189$
Stable Isotope Labeled Zolbetuximab Biosimilar – Anti-CLDN18.2 mAb – Research Grade
SIL

Stable Isotope Labeled Zolbetuximab Biosimilar – Anti-CLDN18.2 mAb – Research Grade

PX-TA1013-SIL 15750$

Contact us

Send us a message from the form below







    Cart (0 Items)

    Your cart is currently empty.

    View Products